INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Stopped The study was terminated due to emergent data from another study and unrelated to safety.

Conditions

• Advanced Malignancies
• Metastatic Cancer

Interventions

• DRUG: INCAGN01876
• DRUG: Epacadostat
• DRUG: Pembrolizumab

Sponsor

Incyte Biosciences International Sàrl